Empagliflozin and left atrial function in patients with type 2 diabetes mellitus and coronary artery disease: insight from the EMPA-HEART CardioLink-6 randomized clinical trial.

Cardiovasc Diabetol · 2024 · PMC11360285 · PMID 39198860

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

difference was apparentno p-value reported

This difference was apparent at day 1 of treatment and was sustained throughout the study duration of 3 months.

also in 830 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.